US Patent Issued to THE NEMOURS FOUNDATION, REGENXBIO on March 11 for "Treatment of mucopolysaccharidosis IVA" (American, Japanese Inventors)

ALEXANDRIA, Va., March 12 -- United States Patent no. 12,247,213, issued on March 11, was assigned to THE NEMOURS FOUNDATION (Wilmington, Del.) and REGENXBIO INC. (Rockville, Md.).

"Treatment of mucopolysaccharidosis IVA" was invented by Shunji Tomatsu (Wilmington, Del.), Kazuki Sawamoto (Tokyo), Subha Karumuthil-Melethil (Germantown, Md.) and Olivier Danos (Princeton, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are gene therapy methods for the treatment of mucopolysaccharidosis type IVA (MPS IVA) involving the use of recombinant adeno-associated viruses (rAAVs) to deliver human N-acetylgalactosamine-6-sulfate sulfatase (hGALNS) to the bone of a human subject diagnosed with MPS IVA. A...